Research advances on chimeric antigen receptor cellular therapy for hepatocellular carcinoma
10.3760/cma.j.cn113884-20211011-00329
- VernacularTitle:嵌合抗原受体细胞疗法治疗肝癌的研究进展
- Author:
Jie SHEN
1
;
Jiacheng ZHANG
;
Jia YU
;
Youming DING
Author Information
1. 武汉大学人民医院肝胆外科，武汉 430060
- Keywords:
Liver neoplasms;
Chimeric antigen receptor cell therapy;
Mechanism;
T cell;
NK cell
- From:
Chinese Journal of Hepatobiliary Surgery
2022;28(3):230-233
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma is one of the most common cancers and causes of cancer-related death in the world, the insidious onset, rapid progression and poor prognosis make the treatment more difficult. At present, the current therapeutic options, include surgical resection, ablation, postoperative recurrenceare still with disadvantages. The efficacy of targeted drug therapy is also unsatisfactory. Immunotherapy is a promising research direction. Immunosuppressants at the molecular level have shown initial success, while adoptive immunocell therapy at the cellular level has also shown promising results, the typical example is chimeric antigen receptor cell therapy. The purpose of this review is to summarize the recent research progress on chimeric antigen receptor cellular therapy in liver cancer.
